Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic Anemia | OncLive

Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic Anemia

November 17, 2018

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.


x